COMPANY INFO
Abridge AI Inc., founded in 2018 by Shivdev Rao, Florian Metze, and Sandeep Konam, is a healthcare technology company headquartered in Pittsburgh, Pennsylvania, with approximately 150-218 employees. The company provides an AI-driven platform that transforms patient-clinician conversations into structured clinical notes, improving clinical documentation efficiency and reducing administrative burden on healthcare providers. Their website is www.abridge.com.
Abridge AI Inc. is a leading healthcare technology company founded in 2018 and headquartered in Pittsburgh, Pennsylvania. Specializing in the health care sector, Abridge leverages artificial intelligence to convert patient-clinician conversations into structured clinical notes, significantly enhancing clinical documentation efficiency and reducing administrative burdens on providers. With a team of over 150 employees, Abridge’s mission is to empower deeper understanding and more meaningful connections in healthcare through advanced AI-driven solutions.
Abridge AI Inc. has experienced remarkable growth in its funding journey, attracting the attention of top venture capitalists and healthcare investors. As of June 24, 2025, Abridge has secured approximately $757.5 million across 9 funding rounds. The company’s funding strategy has centered on scaling its AI platform, expanding clinical capabilities, and penetrating broader markets. Key milestones include a $150 million Series C, a $250 million Series D, and a record-setting $300 million Series E led by renowned investors Andreessen Horowitz (a16z) and Khosla Ventures. Abridge’s impressive fundraising demonstrates strong investor confidence in its vision for AI-powered healthcare documentation and workflow automation.
Series E funding will drive product innovation, particularly in embedding revenue cycle intelligence and care intelligence into clinical workflows, further scaling the platform and expanding its reach within the healthcare industry.
This round supported Abridge’s rapid growth and adoption across major health systems, facilitating further development of AI technology and expansion into new geographies.
Proceeds from Series C were dedicated to building out generative AI capabilities for medical documentation and scaling commercial operations to reach new healthcare markets.
Aimed at accelerating growth, this Series B round supported ongoing market expansion and the rollout of advanced AI features for clinicians.
Later-stage VC funding was focused on product scaling and broadening market reach through new partnerships and enhanced platform development.
Series A financing propelled early product development and initial market entry, allowing Abridge to prove its technology and begin integrating with electronic health records (EHRs).
Seed funding enabled the initial launch of Abridge’s AI platform and supported its foundational product development.
One of Silicon Valley’s most influential venture capital firms, a16z led Abridge’s $300M Series E round, reinforcing the company’s leadership in AI and healthcare technology.
A prominent venture capital investor in disruptive tech and health innovations, Khosla Ventures co-led the Series E round to accelerate Abridge’s product innovation.
A global venture capital firm with a history of backing high-growth technology companies, IVP participated in Abridge’s Series D, supporting its scale-up across health systems.
A leading technology and healthcare venture capital firm, Lightspeed has been a key supporter in Abridge funding rounds, particularly during milestone growth phases.
Redpoint is a major investor with a focus on transformational tech startups, contributing investment to Abridge funding rounds and lending expertise in tech scale-up.
Known for backing next-generation information technology companies, Spark Capital’s involvement has helped Abridge drive market expansion and AI product enhancements.
Focused on healthcare and technology investment, Wittington Ventures participated to help scale operations and enhance Abridge’s platform.
Union Square’s early investment empowered Abridge’s initial product development and EHR integration, laying groundwork for its pioneering AI solutions.
The University of Pittsburgh Medical Center’s investment and clinical partnership have been vital in piloting and optimizing Abridge’s real-world healthcare impact.
A top-tier global VC, Bessemer’s backing underscores confidence in Abridge’s ability to transform healthcare documentation.
Supporting digital health innovations, AIDIF has contributed to ongoing AI research and development at Abridge.
The venture arm of one of America’s largest integrated health systems, Kaiser Permanente Ventures invests to fuel advancements in patient care technologies.
As a major healthcare investor, CVS Health Ventures brings strategic insights and industry connections to support Abridge’s expansion.
Renowned angel investor and technology thought leader, Esther Dyson provides advisory support and strategic capital for Abridge’s long-term mission.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Abridge AI Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.